|1.||Kallend, David: 10 articles (12/2014 - 07/2009)|
|2.||Kastelein, John J P: 6 articles (12/2014 - 05/2002)|
|3.||Burgess, Tracy: 5 articles (10/2011 - 07/2009)|
|4.||Fayad, Zahi A: 4 articles (10/2013 - 08/2011)|
|5.||Tardif, Jean-Claude: 4 articles (11/2012 - 12/2009)|
|6.||Niesor, Eric J: 3 articles (12/2014 - 07/2009)|
|7.||Rudd, James H F: 3 articles (10/2013 - 08/2011)|
|8.||Mani, Venkatesh: 3 articles (10/2013 - 08/2011)|
|9.||Tawakol, Ahmed: 3 articles (10/2013 - 08/2011)|
|10.||Fuster, Valentin: 3 articles (10/2013 - 08/2011)|
|1.||Coronary Disease (Coronary Heart Disease)
01/01/2012 - "Post hoc analysis of dalcetrapib therapy in five placebo-controlled, Phase II trials (4-48 weeks of duration) involving T2DM and/or metabolic syndrome, in dyslipidaemic patients with coronary heart disease (CHD) or CHD risk equivalent. "
10/29/2011 - "In this phase 2b, double-blind, multicentre trial, patients (aged 18-75 years) with, or with high risk of, coronary heart disease were randomly assigned (1:1) to dalcetrapib 600 mg/day or placebo for 24 months. "
06/01/2013 - "Two CETP inhibitors, dalcetrapib and torcetrapib, have been tested in large clinical trials in statin-treated coronary heart disease patients and have shown no clinical benefit compared to placebo. "
01/01/2011 - "As part of the dalcetrapib dal-HEART clinical trial programme, the efficacy and safety of dalcetrapib is assessed in coronary heart disease (CHD) patients in the dal-VESSEL study (ClinicalTrials.gov identifier: NCT00655538), the design and methods of which are presented here. "
04/01/2012 - "Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial."
08/01/2011 - "Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography."
07/01/2012 - "In the dal-PLAQUE atherosclerosis imaging study, dalcetrapib reduced the enlargement of total vessel area over time. "
01/01/2010 - "Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. "
02/01/2004 - "Inhibition of CETP activity by JTT-705 increases HDL levels by increasing the synthesis of apo A-I, suggesting that it could be a promising therapeutic approach for atherosclerosis."
12/01/2002 - "Here we investigated the effects of JTT-705, a chemical inhibitor of CETP, on the development of atherosclerosis in Japanese white rabbits fed on a high cholesterol diet. "
01/01/2011 - "Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of anacetrapib and dalcetrapib for the treatment of dyslipidemia were included. "
01/01/2012 - "Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib."
01/01/2011 - "Inhibition of CETP by anacetrapib and dalcetrapib represents an encouraging development in the management of dyslipidemia, particularly in patients with low HDL-C levels. "
07/01/2012 - "The cholesteryl ester transfer protein modulator dalcetrapib is currently under development for the prevention of dyslipidemia and cardiovascular disease. "
01/01/2011 - "Anacetrapib and dalcetrapib represent a novel treatment option for patients who have dyslipidemia and low levels of high-density lipoprotein cholesterol (HDL-C). "
05/07/2002 - "In a randomized, double-blind, and placebo-controlled trial, we evaluated the efficacy and safety of daily treatment with 300, 600, and 900 mg JTT-705 in 198 healthy subjects with mild hyperlipidemia. "
01/01/2009 - "In patients with type II hyperlipidemia, CETP inhibition with JTT-705 increased HDL-C and lowered triglycerides but improved endothelial function in the subgroup of patients with low baseline HDL-C levels only."
03/01/2004 - "JTT-705 is a cholesteryl ester transfer protein inhibitor under development by Japan Tobacco Inc for the treatment of hyperlipidemia. "
01/01/2009 - "As such, the aim of the present study was to investigate whether CETP-inhibition with JTT-705, a molecule distinctly different from torcetrapib, impacts on vascular function, a well-established surrogate of atherosclerotic vascular disease, as well as markers of inflammation and oxidative stress in patients with type II hyperlipidemia. "
11/01/2009 - "Three key findings predicted from model simulations are: 1) net CE transfer activity from HDL to VLDL and LDL can be significantly altered by changing the balance of homoexchange versus heteroexchange of neutral lipids via CETP; 2) lipemia-induced increases in CETP activity are more likely caused by increases in lipoprotein particle size than particle number; and 3) the inhibition mechanisms of the CETP inhibitors torcetrapib and JTT-705 are significantly more potent than a classic competitive inhibition mechanism with the irreversible binding mechanism having the most robust response. "
|5.||Cardiovascular Diseases (Cardiovascular Disease)
04/01/2012 - "These results suggest that modulating CETP with dalcetrapib may be a beneficial mechanism in cardiovascular disease. "
04/01/2012 - "Dalcetrapib--restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease."
01/01/2012 - "Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk."
08/01/2011 - "Results from ongoing clinical outcomes studies with anacetrapib and dalcetrapib will clarify the relevance of CETP inhibition versus modulation towards HDL remodelling in the treatment of cardiovascular diseases."
01/01/2011 - "Results of future trials are much anticipated, as these will clarify the role of anacetrapib and dalcetrapib in reduction of cardiovascular disease."
|4.||Niacin (Nicotinic Acid)
|7.||glucuronyl glucosamine glycan sulfate (Vessel)
|8.||Cholesterol Ester Transfer Proteins
|9.||Apolipoprotein A-I (Apolipoprotein A1)
|1.||Cardiac Resynchronization Therapy
|4.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)